STOCK TITAN

Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Purple Biotech (PPBT) presented preclinical tumor-killing data for IM1240, its lead antibody targeting 5T4, at the EORTC-NCI-AACR Symposium. IM1240 showed activity in patient-derived head and neck, bladder and lung tumor specimens collected after immunotherapy-containing regimens. In a lung tumor specimen, its pathologic response score was 94 out of 100, versus 49 with an inactive NKG2A arm and 38 when CD3 activation was prevented.

In non-human primates, IM1240 showed lower systemic cytokine release, an approximately 8-fold longer half-life and 16-fold greater systemic exposure than an uncapped variant. Purple Biotech is advancing IM1240 toward clinical testing.

Loading...
Loading translation...

Positive

  • Minor pointIM1240 tumor-killing activity was observed in patient-derived head and neck, bladder and lung specimens after immunotherapy-containing regimens
  • Minor pointLung tumor response score reached 94 on a 0–100 scale, versus 49 with inactive NKG2A and 38 with CD3 activation blocked
  • Minor pointSystemic cytokine responses in non-human primates were lower with IM1240 than with an uncapped variant, even at higher doses
  • Minor pointIM1240 half-life in non-human primates was approximately 8-fold longer than with an uncapped variant
  • Minor pointIM1240 systemic exposure in non-human primates was 16-fold greater than with an uncapped variant
2 minor points
  • Minor pointCD3 cap removal restored CD3 binding and immune-cell-mediated tumor killing in preclinical testing
  • Minor pointIM1240 development is advancing toward clinical testing

Negative

  • None.

News Explained

IM1240 targets 5T4 and combines a CD3 arm designed to stay inactive in circulation until tumor proteases remove its cap with an NKG2A arm intended to block an inhibitory immune checkpoint affecting NK cells and some cytotoxic T cells.

Key Figures

In situ pathologic response score: 94 on a 0–100 scale Comparator response score: 49 on a 0–100 scale Non-cleavable-cap response score: 38 on a 0–100 scale +4 more
In situ pathologic response score
94 on a 0–100 scale
Patient-derived NSCLC explant treated with IM1240
Comparator response score
49 on a 0–100 scale
Otherwise comparable antibody with an inactivated NKG2A-binding arm
Non-cleavable-cap response score
38 on a 0–100 scale
NSCLC explant; CD3 activation prevented
Half-life
approximately 8-fold longer
IM1240 versus a non-capped variant in non-human primates
Systemic exposure
16-fold greater
IM1240 versus a non-capped variant in non-human primates
IM1240 dose with minimal IL-6 and TNF-α
10 mg/kg
Preclinical non-human-primate study
Non-capped variant dose with robust cytokine release
0.03 mg/kg
IM1222 in non-human primates

Historical Context

2 past events · Latest: Aug 07
2 events
  1. Aug 07

    IM1240 preclinical data

    24h Move
    +1.4%

    Reported NKG2A-dependent tumor activity and longer half-life and greater exposure versus a non-capped variant.

  2. Jun 11

    IM1240 preclinical data

    24h Move
    -48.0%

    Presented activity in resistant tumor samples and non-human-primate safety and exposure findings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nkg2a, cd3, 5t4, pharmacokinetic
4 terms
nkg2a medical
"an NKG2A arm that blocks an inhibitory immune checkpoint"
NKG2A is a protein “switch” found on certain immune cells that tells them to hold back from attacking other cells; it acts like a brake on the immune response by sensing signals from healthy or cancerous cells. It matters to investors because drugs that block this switch can release the brake, potentially boosting the immune system’s ability to kill tumors—making NKG2A a promising target that can drive clinical trial results, approvals, and company valuations.
cd3 medical
"a capped CD3 arm designed to penetrate into solid cancers"
CD3 is a group of proteins on the surface of T cells, the immune system’s front-line soldiers, that act like a control panel to turn those cells on and off. It matters to investors because many modern therapies work by engaging or blocking CD3 to direct T cells against cancer or dampen harmful immune reactions; success, safety and regulatory approval of CD3-targeting drugs can significantly affect a biotech company’s prospects.
5t4 medical
"IM1240, targeting 5T4, an oncofetal antigen"
5T4 is a protein found on the surface of many tumor cells but rarely on normal healthy tissue, making it a recognizable marker cancer treatments and diagnostic tests can target. For investors, it matters because drugs or tests that reliably identify or attack cells with this marker can become valuable products if they improve detection or treatment outcomes, but they also carry typical clinical and regulatory development risks — think of it as a visible flag that helps doctors locate and treat disease.
pharmacokinetic medical
"the favorable safety and pharmacokinetic profile"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against cancers expressing antigens of interest while overcoming inhibitory signals that constrain anti-tumor immunity.
  • CAPTN-3 antibodies combine an NKG2A arm that blocks an inhibitory immune checkpoint with a capped CD3 arm designed to penetrate into solid cancers and activate T cells only within the tumor microenvironment, distinguishing the platform from conventional T-cell engagers that activate T cells before reaching their target.
  • IM1240, targeting 5T4, an oncofetal antigen expressed on a wide range of cancers, demonstrated potent anti-tumor activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy, including a muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab.
  • NKG2A engagement is a key contributor to tumor killing, as demonstrated in studies using IM1240 and matched antibody variants in patient-derived cancer specimens, supporting the platform's strategy of targeting both innate and adaptive immune responses.
  • In non-human primates, CD3 capping markedly reduced cytokine release and extended systemic exposure compared with a non-capped variant, with an approximately 8-fold longer half-life and 16-fold greater exposure, further supporting the potential of IM1240 to combine potent anti-tumor activity with a broad therapeutic window.

REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.

CAPTN-3 is Purple Biotech's platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform's lead candidate, targets 5T4.

The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.

"One of the central challenges in cancer immunotherapy is that the presence of cytotoxic immune cells within a tumor does not necessarily translate into effective tumor control. A major blind spot when introducing novel drugs is the assumption that cancer is stagnant in the face of frontline therapies," said Dr. Amir Horowitz. "Our research on the HLA-E/NKG2A pathway has shown how tumors can exploit inhibitory signals to restrain otherwise capable natural killer (NK) cells and T cells. The IM1240 findings provide compelling preclinical evidence for a therapeutic strategy that combines tumor-directed T-cell engagement with relief of NKG2A-mediated immune suppression. The activity observed in treatment-resistant human tumor models is particularly encouraging and warrants further investigation."

"These findings address two key challenges in developing T-cell engagers for solid cancers: immune resistance and systemic immune activation," said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. "Our objective is not simply to recruit more immune cells to cancers, but to enable a more effective anti-tumor response by combining targeted immune engagement with the ability to counteract inhibitory mechanisms within the tumor microenvironment. The contribution of the NKG2A arm in immunotherapy-resistant human cancers, together with the favorable safety and pharmacokinetic profile of our CD3 capping technology, strengthens the scientific foundation as we advance IM1240 toward the clinic."

Presentation Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety

Abstract: ENA26-0137
Session: Plenary Session 7 – Proffered Papers: Novel Agents and Targets
Date and Time: Friday, November 20, 2026, 15:24 CET

Addressing immune resistance beyond T-cell recruitment

While T-cell engagers are designed to bring cytotoxic T cells into contact with cancer cells, their activity may remain limited by immunosuppressive mechanisms within the tumor microenvironment. One such mechanism is the HLA-E/NKG2A immune checkpoint: HLA-E, expressed by tumor cells, binds the inhibitory NKG2A receptor on NK cells and subsets of cytotoxic T cells, suppressing their anti-tumor function.

Dr. Horowitz's work has helped establish the HLA-E/NKG2A pathway as an important regulator of anti-tumor immunity. Recent research from his laboratory, posted as a preprint, found that bladder cancers unresponsive to BCG immunotherapy can retain populations of potentially cytotoxic immune cells while exhibiting increased HLA-E/NKG2A inhibitory interactions. Experimental blockade of NKG2A restored immune-cell function in patient-derived tumor co-cultures, highlighting a potentially actionable mechanism of immune resistance.

These observations reinforce the scientific rationale underlying CAPTN-3: effective anti-tumor immunity may require not only bringing immune cells to cancer cells but also overcoming the inhibitory signals that prevent those immune cells from functioning effectively.

IM1240 integrates three complementary functions within a single antibody: recognition of the tumor-associated antigen 5T4, capped CD3-mediated T-cell redirection, and NKG2A engagement designed to block inhibitory signaling affecting NK cells and cytotoxic T cells. 5T4 is expressed in a variety of solid cancers and is associated with advanced disease and poor clinical outcomes.

NKG2A engagement enhances IM1240's anti-tumor activity

Data presented at ENA 2026, building on data first presented at the EACR 2026 Annual Congress in June, demonstrated that IM1240 induced anti-tumor activity in patient-derived tumor specimens collected following prior immunotherapy-containing treatment regimens: six head and neck squamous cell carcinoma metastatic lymph node samples, one muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab, and one non-small cell lung cancer (NSCLC) tumor resistant to neoadjuvant chemotherapy plus PD-1 blockade. In the dissociated head and neck and bladder specimens, tumor-cell killing required functional CD3 and NKG2A arms; in cancer cell lines, activity depended on 5T4 expression.

In a patient-derived NSCLC explant obtained following chemotherapy and PD-1 inhibitor treatment, IM1240 demonstrated substantially greater anti-tumor activity, achieving an in situ pathologic response score of 94 on a 0–100 scale, compared with 49 for an otherwise comparable antibody with an inactivated NKG2A-binding arm. Similarly, preventing CD3 activation with a non-cleavable cap reduced the response score to 38, highlighting the critical contribution of both functional components to IM1240's anti-tumor activity.

Spatial imaging of treated NSCLC explants revealed differences in immune-cell distribution and cell-cell interactions between IM1240 and the NKG2A-inactive comparator, suggesting that NKG2A engagement may influence not only direct tumor-cell killing but also the broader immune organization of the tumor microenvironment.

Collectively, these findings provide functional evidence that incorporating NKG2A targeting into a capped T-cell engager can enhance anti-tumor activity beyond CD3-mediated T-cell redirection alone.

CD3 capping supports a favorable safety and pharmacokinetic profile

In addition to its multi-arm immune mechanism, IM1240 incorporates Purple Biotech's proprietary protease-cleavable CD3 capping technology, designed to restrict full T-cell engagement until the antibody encounters proteolytic conditions associated with the tumor microenvironment.

The ENA presentation also shows that protease-mediated cap removal restores CD3 binding and immune-cell-mediated tumor killing, while a non-cleavable control remains functionally restricted.

Preclinical non-human primate studies further demonstrated that this capping strategy substantially reduced systemic cytokine responses compared with a non-capped antibody, even at higher doses, and prolonged systemic exposure through reduced clearance. As previously reported, IM1240 induced minimal IL-6 and TNF-α at 10 mg/kg, whereas the non-capped variant, IM1222, induced robust cytokine release at just 0.03 mg/kg. IM1240 also showed an approximately 8-fold longer half-life and 16-fold greater systemic exposure.

Together, these findings support a design in which IM1240 circulates with its CD3 arm capped and is activated within the tumor microenvironment, potentially allowing sustained exposure while limiting premature peripheral T-cell activation.

About CAPTN-3

CAPTN-3 is Purple Biotech's proprietary platform of capped tri-specific antibodies designed to combine tumor-antigen recognition, T-cell engagement, and NKG2A-mediated immune checkpoint modulation. The platform integrates a protease-cleavable CD3 capping mechanism intended to limit systemic T-cell activation while enabling anti-tumor activity within the tumor microenvironment.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology is designed to confine immune activation to the tumor microenvironment and, based on preclinical data, to expand the therapeutic window compared to conventional T-cell engagers. The platform's lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue", "potential", "designed to" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Purple Biotech’s IM1240 perform in the preclinical lung cancer model?

IM1240 achieved a pathologic response score of 94 on a 0–100 scale in a patient-derived non-small cell lung cancer specimen. A comparable antibody with an inactive NKG2A arm scored 49, while a version with a cap that prevented CD3 activation scored 38.

What prior treatments had the bladder and lung tumors resisted in Purple Biotech’s IM1240 study?

The bladder tumor had resisted enfortumab vedotin plus pembrolizumab, and the lung tumor had resisted chemotherapy plus PD-1 blockade given before surgery. The specimens came from a muscle-invasive bladder cancer and a non-small cell lung cancer.

What did Purple Biotech’s IM1240 primate study show about inflammatory signals?

In non-human primates, IM1240 triggered minimal release of IL-6 and TNF-α at 10 mg/kg. The uncapped variant, IM1222, triggered a pronounced release of cytokines, which are immune signaling proteins, at 0.03 mg/kg.

Keep reading